Evidence map›Paper›PMID 37938576›Full record

ArticleNature communications2023

Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.

Derek Lee, Zachary Spencer Dunn, Wenbin Guo, Carl J Rosenthal, Natalie E Penn, Yanqi Yu, Kuangyi Zhou, Zhe Li, Feiyang Ma, Miao Li and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. γδ T cells in colorectal and liver cancer.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Derek Lee *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID 0000-0003-4613-0233
Zachary Spencer Dunn *Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID 0000-0003-2500-6006
Wenbin Guo *Bioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA.ORCID 0000-0002-3916-0314
Carl J RosenthalDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Natalie E PennDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Yanqi YuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID 0000-0002-6969-3752
Kuangyi ZhouDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Zhe LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Feiyang MaDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, CA, USA.ORCID 0000-0002-6260-0787
Miao LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Tsun-Ching SongDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Xinjian CenDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.ORCID 0000-0002-1663-1347
Yan-Ruide LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA.
Jin J ZhouDepartment of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA.
Matteo PellegriniBioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA.ORCID 0000-0001-9355-9564
Pin WangMork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-4132-105X
Lili YangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA, USA. liliyang@ucla.edu.ORCID 0000-0001-6568-0404

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Homero Erwin del Pino · 2022 to 2026
$15.6M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
MULTIDISCIPLINARY TRAINING IN MICROBIAL PATHOGENESIST32AI007323 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peter John Bradley · 1988 to 2026
$8.6M
Genomics, GPUs, and Next Generation Computational StatisticsR01HG006139 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SOBEL, ERIC · 2011 to 2023
$5.1M
A Role for Glycemic Variation in Optimizing Management of Diabetes and Vascular ComplicationsR21HL150374 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REAVEN, PETER D, ZHOU, JIN · 2020 to 2021
$250k
NCI NIH HHS P30 CA016042NCI NIH HHS T32 CA009120NHGRI NIH HHS R01 HG006139NHLBI NIH HHS R21 HL150374NIAID NIH HHS P30 AI152501NIAID NIH HHS T32 AI007323
6 · The paper itself

Abstract

Allogeneic Vγ9Vδ2 (Vδ2) T cells have emerged as attractive candidates for developing cancer therapy due to their established safety in allogeneic contexts and inherent tumor-fighting capabilities. Nonetheless, the limited clinical success of Vδ2 T cell-based treatments may be attributed to donor variability, short-lived persistence, and tumor immune evasion. To address these constraints, we engineer Vδ2 T cells with enhanced attributes. By employing CD16 as a donor selection biomarker, we harness Vδ2 T cells characterized by heightened cytotoxicity and potent antibody-dependent cell-mediated cytotoxicity (ADCC) functionality. RNA sequencing analysis supports the augmented effector potential of Vδ2 T cells derived from CD16 high (CD16

Indexed as

Hematopoietic Stem Cell TransplantationOvarian NeoplasmsBiomarkersFemaleHumansInterleukin-15BiomarkersInterleukin-15

Identifiers

PMID37938576
PMCPMC10632431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.